Last reviewed · How we verify
autologous CAR.CD30 EBV specific-CTLs
Autologous CAR.CD30 EBV-specific CTLs are a novel cell therapy in development by Baylor College of Medicine for the treatment of CD30+ lymphomas. This Phase 1 trial is currently active but not recruiting, with a focus on safety and efficacy.
At a glance
| Generic name | autologous CAR.CD30 EBV specific-CTLs |
|---|---|
| Also known as | CD30 EBV CTL |
| Sponsor | Baylor College of Medicine |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: